<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Trends Pharmacol Sci</journal-id>
      <journal-title>Trends in Pharmacological Sciences</journal-title>
      <issn pub-type="ppub">0165-6147</issn>
      <issn pub-type="epub">1873-3735</issn>
      <publisher>
        <publisher-name>Published By Elsevier In Association With The International Union Of Pharmacology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2809215</article-id>
      <article-id pub-id-type="pmid">19969380</article-id>
      <article-id pub-id-type="publisher-id">TIPS752</article-id>
      <article-id pub-id-type="doi">10.1016/j.tips.2009.10.006</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Opinion</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Protein kinase Cα: disease regulator and therapeutic target</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Konopatskaya</surname>
            <given-names>Olga</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Poole</surname>
            <given-names>Alastair W.</given-names>
          </name>
          <email>a.poole@bris.ac.uk</email>
        </contrib>
      </contrib-group>
      <aff>
        <addr-line>Department of Physiology &amp; Pharmacology, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK</addr-line>
      </aff>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2010</year>
      </pub-date>
      <volume>31</volume>
      <issue>1</issue>
      <fpage>8</fpage>
      <lpage>14</lpage>
      <history/>
      <permissions>
        <copyright-statement>© 2010 Elsevier Ltd.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p>
        </license>
      </permissions>
      <abstract>
        <p>Protein kinase Cα (PKCα) is a member of the AGC (which includes PKD, PKG and PKC) family of serine/threonine protein kinases that is widely expressed in mammalian tissues. It is closely related in structure, function and regulation to other members of the protein kinase C family, but has specific functions within the tissues in which it is expressed. There is substantial recent evidence, from gene knockout studies in particular, that PKCα activity regulates cardiac contractility, atherogenesis, cancer and arterial thrombosis. Selective targeting of PKCα therefore has potential therapeutic value in a wide variety of disease states, although will be technically complicated by the ubiquitous expression and multiple functions of the molecule.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Protein kinase C (PKC) is a family of serine/threonine protein kinases that regulate various cellular functions, including adhesion, secretion, proliferation, differentiation and apoptosis. The family is classified into three groups on the basis of the arrangement of their regulatory domains w2<xref rid="bib1" ref-type="bibr">[1]</xref>. Conventional isoforms (cPKC; α, β, γ) contain a diacylglycerol (DAG)/phorbol ester-binding C1 domain and a Ca<sup>2+</sup>-binding C2 domain. Novel isoforms (nPKC; δ, ɛ, η, θ) also contain C1 domains, but their C2 domains are unable to bind Ca<sup>2+</sup>. Atypical isoforms (aPKC; ζ and ι/λ) lack a C2 domain and have an atypical C1 domain, and are therefore regulated independently of Ca<sup>2+</sup> or DAG.</p>
      <p>Here we focus on PKCα because of recent evidence, particularly derived from genetic studies, implicating this kinase in several major disease processes <xref rid="bib2 bib3 bib4" ref-type="bibr">[2–4]</xref>, and because of the multiple approaches that may be adopted to target PKCα pharmacologically <xref rid="bib5 bib6 bib7" ref-type="bibr">[5–7]</xref>. PKCα is widely expressed and being a conventional PKC isoform, it may be regulated downstream of the multitude of receptors that couple to activation of phospholipase C, including Gq-coupled GPCRs (G-protein-coupled receptors), growth factor receptors and adhesion receptors. Pharmacological studies have shown PKCα to regulate multiple biological processes, including cell proliferation, apoptosis, differentiation, migration and adhesion. These roles are described and discussed elsewhere <xref rid="bib1 bib8 bib9 bib10" ref-type="bibr">[1,8–10]</xref> and are outside of the scope of this article. The more recent introduction of PKCα gene knockout (<italic>Prkca</italic><sup>−/−</sup>) mice has provided definitive evidence for the function of this kinase in physiological processes including insulin coupling to PI3kinase <xref rid="bib11" ref-type="bibr">[11]</xref>, and immune cell functions such as IgG class switching <xref rid="bib12" ref-type="bibr">[12]</xref> and down-regulation of the T cell receptor <xref rid="bib13" ref-type="bibr">[13]</xref>, such as prostate and breast cancer, heart failure and pulmonary disease.</p>
      <p>PKCα gene knockout mice are now also revealing critical roles for this gene in disease processes. In this opinion, we concentrate on the role of PKCα in the three best studied of these: cardiovascular dysfunction, arterial thrombosis and cancer (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). We suggest that, through a variety of pharmacological strategies (<xref rid="tb1" ref-type="boxed-text">Box 1</xref>), PKCα may emerge as a key target in the future treatment and management of these diseases.</p>
    </sec>
    <sec>
      <title>PKCα in cardiovascular disease regulation</title>
      <sec>
        <title>Heart failure</title>
        <p>It has been established that various PKC isoforms, including PKCα, contribute to impaired left ventricular filling and ejection in heart failure <xref rid="bib6" ref-type="bibr">[6]</xref>. PKCα is both necessary and sufficient to induce cardiomyocyte hypertrophy - an adaptive mechanism triggered by decreased cardiac output and, if sustained, leading to heart failure and death - by an increase in protein synthesis, protein-DNA ratio, and cell surface area <xref rid="bib14" ref-type="bibr">[14]</xref>. Further, PKCα antisense treatment reduces phenylephrine-induced increases in α-actin mRNA and atrial natriuretic peptide secretion <xref rid="bib15" ref-type="bibr">[15]</xref>, thereby causing a loss of some markers of pathological hypertrophy. Overexpression of PKCα also increases cardiomyocyte surface area and atrial natriuretic peptide expression, indicating that PKCα activation induces cardiomyocyte hypertrophy <xref rid="bib16" ref-type="bibr">[16]</xref>.</p>
        <p>This regulation of cardiac hypertrophy translates into end-stage heart failure, and in animal models of this disease, expression and activity of PKCα are up-regulated <xref rid="bib17" ref-type="bibr">[17]</xref>. Ablation of myocardial PKCα by targeted gene knockout leads to increased myocardial contractility, whereas transgenic overexpression of PKCα results in ventricular dysfunction and alterations in Ca<sup>2+</sup> homeostasis <xref rid="bib3" ref-type="bibr">[3]</xref>. The mechanism of PKCα-dependent depression of myofilament contractility involves phosphorylation of the cardiac troponins cTnI and/or cTnT functionally important in controlling maximum tension, ATPase activity, and Ca<sup>2+</sup> sensitivity of the myofilaments <xref rid="bib18" ref-type="bibr">[18]</xref>.</p>
      </sec>
      <sec>
        <title>Atherosclerosis</title>
        <p>Atherosclerosis is a disease of large and medium-sized vessels that involves multiple cells and processes including endothelial dysfunction, inflammation and proliferation. In the arterial wall the disease is characterized by the emergence in the intima of atherosclerotic fatty streaks, later transforming into plaques, consisting of connective tissue and some smooth muscle cells (SMCs). It is accompanied by thickening and hardening (sclerosis) of the arterial wall, loss of elasticity due to infiltration of the intima with mononuclear cells, SMCs, and increased endothelial cell depositions. Atherosclerosis designates a special form of arteriosclerosis that is additionally characterized by the occurrence of foam cells, that is, lipid-laden macrophages and SMCs that may rupture and release their contents into the lesional areas. There is substantial evidence that PKCα plays key roles in these processes.</p>
      </sec>
      <sec>
        <title>Endothelial cell proliferation</title>
        <p>Pathological angiogenesis has been implicated in a number of vascular diseases, including unstable atherosclerotic plaque development <xref rid="bib19" ref-type="bibr">[19]</xref>. Although there are some reports to the contrary <xref rid="bib20 bib21" ref-type="bibr">[20,21]</xref>, PKCα has generally been shown to be a positive regulator of angiogenesis <xref rid="bib22" ref-type="bibr">[22]</xref>, involving the processes of endothelial cell migration, adhesion and tube formation mediated by vascular endothelial growth factor (VEGF).</p>
        <p><italic>In vivo</italic>, knockdown of PKCα prevents myocardial vessel formation in a murine model of myocardial infarction <xref rid="bib23" ref-type="bibr">[23]</xref>. There seems to be positive feedback between the two signalling components, PKCα and VEGF, because VEGF expression in endothelial cells depends on PKCα, but in turn VEGF leads to activation of PKCα <xref rid="bib24" ref-type="bibr">[24]</xref>. Overexpression of a PKCα pseudosubstrate inhibitory peptide also slows the rate of endothelial cell migration <xref rid="bib25" ref-type="bibr">[25]</xref>. Additionally, PKCα mediates interleukin-1β-induced expression of matrix metalloproteinase-2, a molecule implicated in angiogenesis <xref rid="bib26" ref-type="bibr">[26]</xref>.</p>
      </sec>
      <sec>
        <title>Endothelial barrier function</title>
        <p>Endothelial permeability is tightly regulated by a balance of contractile forces generated by the cytoskeleton and adhesive forces generated by cell–cell and cell–matrix contact <xref rid="bib27" ref-type="bibr">[27]</xref>. Early studies suggested that PKC mediates the acute rise in endothelial permeability <italic>in vitro</italic>, via receptor-mediated (e.g. through thrombin, histamine or bradykinin receptors), or receptor-independent (by oxidants or shear stress) increases in phospholipase C activity <xref rid="bib28" ref-type="bibr">[28]</xref>. Subsequently, several studies have narrowed this effect specifically to PKCα and its role in endothelial cell contraction and disassembly of VE-cadherin junctions <xref rid="bib29 bib30" ref-type="bibr">[29,30]</xref>.</p>
        <p>At the molecular level, the mechanism might involve PKCα-dependent regulation of transient receptor potential canonical-1 (TRPC-1) channels <xref rid="bib31" ref-type="bibr">[31]</xref> and Rho GTPases <xref rid="bib32 bib33" ref-type="bibr">[32,33]</xref>. The increase in pulmonary endothelial cell permeability caused by TNFα is also associated with an increase in PKCα activity <xref rid="bib34" ref-type="bibr">[34]</xref>, and protein phosphatase type 2B (PP2B), which might regulate PKCα activity, is also implicated in regulating the permeability of pulmonary endothelial cells <xref rid="bib35" ref-type="bibr">[35]</xref>.</p>
        <p>Lastly, endothelial permeability is altered in diabetes mellitus, and PKCα has been shown to mediate glucose-induced increases in endothelial cell permeability <xref rid="bib36" ref-type="bibr">[36]</xref>. Therefore, there is high consensus among data supporting the idea that PKCα positively regulates endothelial permeability through various molecular mechanisms.</p>
      </sec>
      <sec>
        <title>Oxidative stress and monocyte adhesion</title>
        <p>Endothelial cell dysfunction elicited by oxidative stress plays a critical role in the pathogenesis of atherosclerosis <xref rid="bib37" ref-type="bibr">[37]</xref>. Low-density lipoproteins (LDLs) may be oxidized when excessive free radicals react with the lipoproteins. In turn, these oxidized LDLs (Ox-LDLs) become deposited in the arterial walls and can lead to plaque development by stimulating macrophage uptake and foam cell formation.</p>
        <p>A detrimental feedback loop operates in endothelial cells, where superoxides lead to generation of Ox-LDLs, which in turn stimulate further superoxide generation. Fleming <italic>et al.</italic> <xref rid="bib38" ref-type="bibr">[38]</xref> have shown that Ox-LDL stimulation of endothelial cells leads to uncoupling of endothelial nitric oxide synthase (eNOS) from its generation of nitric oxide, and a greater accumulation of superoxide free radicals. The signalling pathway in endothelial cells from Ox-LDL to eNOS has been attributed to inactivation and down-regulation of PKCα, which results in diminished phosphorylation of eNOS on Thr-495 <xref rid="bib38" ref-type="bibr">[38]</xref>.</p>
        <p>Additionally, PKCα in inflammatory cells might mediate their adhesion to and interaction with endothelial cells. The adhesion of circulating monocytes to endothelial cells contributes importantly to the inflammatory aspects of atherogenesis, which describes the development of atherosclerotic plaques. Pre-incubation of monocytes with Gö6976, the inhibitor of classical PKC isoforms, significantly reduces monocyte adhesion to HUVECs (human umbilical vein endothelial cells) <xref rid="bib39" ref-type="bibr">[39]</xref>. Another inflammatory mediator, apolipoprotein CIII, a constituent of apolipoprotein B, enhances the adhesion of monocytes to endothelial cells via PKCα-mediated β1-integrin activation <xref rid="bib40" ref-type="bibr">[40]</xref>. Lastly, endothelial cell PKCα is important in also regulating inflammatory cell adhesion, through expression of the adhesion molecule PECAM-1 <xref rid="bib41" ref-type="bibr">[41]</xref>, and through regulating exocytosis and surface expression of P-selectin, which mediates neutrophil-endothelial cell interaction <xref rid="bib42" ref-type="bibr">[42]</xref>.</p>
        <p>In summary, although there is a mixed picture in terms of the role of PKCα in atherogenesis and cardiomyocyte hypertrophy, there is reasonable consensus that, on balance, inhibitors of PKCα are likely to be useful in the management of these diseases.</p>
      </sec>
    </sec>
    <sec>
      <title>Platelet function and thrombosis</title>
      <p>Platelets play a central role in mediating atherothrombosis, characterized by an unpredictable atherosclerotic plaque disruption, and are therefore the target of numerous therapies aimed at reducing their activity, particularly in the prevention of coronary artery thrombosis in heart attacks <xref rid="bib43" ref-type="bibr">[43]</xref>. PKC has been established, largely by pharmacological studies, as a major regulator of multiple platelet activities <xref rid="bib44" ref-type="bibr">[44]</xref>, and it is increasingly clear that the different isozymes of PKC expressed in platelets perform distinct functions.</p>
      <p>On activation, platelets release a multitude of active substances from secretory granules, essential for platelet pro-aggregatory responses and development of a stable thrombus in arteries. Yoshioka <italic>et al.</italic> <xref rid="bib45" ref-type="bibr">[45]</xref> have analyzed the mechanisms governing Ca<sup>2+</sup>-induced secretion of α-granules and dense-core granules in permeabilized human platelets, and identified PKCα as an essential component of the mechanism. Using similar biochemical approaches, the same group demonstrated that PKCα is also involved in the regulation of Ca<sup>2+-</sup>induced platelet aggregation <xref rid="bib46" ref-type="bibr">[46]</xref>. Pula <italic>et al.</italic> <xref rid="bib47" ref-type="bibr">[47]</xref> have shown that two tyrosine kinases, Syk and Src, physically interact with PKCα, leading to distinct functional consequences. Although they found that PKCα activity was dependent on Syk, Syk activity was not regulated by PKCα; however, Src activity was negatively regulated by PKCα. These results suggest that PKCα is an important factor in the complex interaction with tyrosine kinases for regulation of functional activities in platelets. Additionally, in a recent elegant study reconstructing the signalling pathway regulating platelet integrin α<sub>IIb</sub>β<sub>3</sub> in a heterologous cell system, it was shown that PKCα expression is required for activation of the integrin through the Rap1 pathway <xref rid="bib48" ref-type="bibr">[48]</xref>. Key molecular functions of platelet activation are therefore mediated by PKCα.</p>
      <p>On the basis of pharmacological data, the specificity of the role played by PKCα has been a contentious issue, due to the lack of selectivity of the reagents available. We have therefore developed a genetic approach using PKCα knockout (<italic>Prkca</italic><sup>−/−</sup>) mice to determine the role of PKCα in regulating platelet function and thrombus formation <xref rid="bib4" ref-type="bibr">[4]</xref>. With regard to the suggested role of PKCα in regulating secretion of dense- and α-granules <xref rid="bib45" ref-type="bibr">[45]</xref>, we were able to confirm definitively that secretion of these granules was substantially diminished in <italic>Prkca</italic><sup>−/−</sup> platelets. <italic>Prkca</italic><sup>−/−</sup> platelets showed significantly reduced functionally relevant phosphorylation on Ser95 of synaptosomal associated protein SNAP-23, an essential component of the membrane fusion machinery and an important regulator of vesicle docking and fusion <xref rid="bib4" ref-type="bibr">[4]</xref>. This observation therefore may potentially explain the observed secretion defect in PKCα-deficient platelets.</p>
      <p>In addition, <italic>Prkca</italic><sup>−/−</sup> platelets show a marked knockdown in activation of integrin α<sub>IIb</sub>β<sub>3</sub> in response either to thrombin or collagen-related peptide, paralleling a deficit in their ability to undergo aggregation at submaximal concentrations of agonist. This is also consistent with the impaired ability of <italic>Prkca</italic><sup>−/−</sup> platelets to form a thrombus <italic>in vitro</italic> in blood flowing over a collagen-coated surface and in an <italic>in vivo</italic> laser-induced model of thrombus formation (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). The defect in secretion was shown, however, to be the central significant event, because addition of exogenous ADP (adenosine diphosphate), the major constituent released from platelet dense granules, rescued the deficits in responses seen in <italic>Prkca</italic><sup><italic>−/−</italic></sup> platelets, confirming that granule secretion is likely to be the primary function for PKCα.</p>
      <p>These findings, together with the fact that <italic>Prkca</italic><sup>−/−</sup> mice do not demonstrate any evidence of overt bleeding, have revealed that PKCα is a potential drug target for antithrombotic therapy, because selective inhibitors would be expected to exert a major effect on thrombus formation while sparing primary platelet adhesive functions.</p>
    </sec>
    <sec>
      <title>PKCα in cancer</title>
      <p>PKCα has long been recognized to have a role in regulating aspects of tumor growth and development <xref rid="bib10" ref-type="bibr">[10]</xref>, although this role is clearly complex and highly tissue-dependent because in some cases it acts as a tumor promoter, and in others it functions as a tumor suppressor. Nonetheless, PKC in general has, for many years, been a drug target for the treatment of cancer. Pharmacological approaches to control of cancer by PKC inhibitors have been discussed elsewhere <xref rid="bib7 bib49" ref-type="bibr">[7,49]</xref> and some of these approaches for PKCα are discussed in <xref rid="tb1" ref-type="boxed-text">Box 1</xref>.</p>
      <p>Its most consistent role is probably regulation of cell motility, and certainly PKCα activation can result in increased cell motility in several <italic>in vivo</italic> and <italic>in vitro</italic> cancer models, the effect of which may be reversed on PKCα inhibition<xref rid="bib50 bib51" ref-type="bibr">[50,51]</xref>. However, the predominant overall picture is of a lack of consistency, which can be illustrated by its differing expression patterns in different tumors. Overexpression of PKCα has been demonstrated in tissue samples of prostate, endometrial, high-grade urinary bladder and hepatocellular cancers<xref rid="bib52 bib53 bib54 bib55" ref-type="bibr">[52–55]</xref>, while for haematological malignancies up- or down-regulation of PKCα has been described <xref rid="bib56" ref-type="bibr">[56]</xref>, and in basal cell carcinoma and colon cancers, down-regulation of PKCα has been observed <xref rid="bib2 bib57" ref-type="bibr">[2,57]</xref>. A mixed picture also pertains to breast cancer cells, where it has been studied extensively. Whereas activation or over-expression of PKCα has been shown in breast cancer cells and in breast tumor samples by some <xref rid="bib58 bib59" ref-type="bibr">[58,59]</xref>, down-regulation has been demonstrated by others <xref rid="bib60" ref-type="bibr">[60]</xref>.</p>
      <p>In terms of cancer therapeutics, PKCα has been a target for the drug aprinocarsen (ISIS 3521; see also <xref rid="tb1" ref-type="boxed-text">Box 1</xref>), a phosphorothioate antisense oligonucleotide (ASO) that targets the 3’-untranslated region of human PKCα mRNA, leading to decreased expression of the protein <xref rid="bib61" ref-type="bibr">[61]</xref>. Aprinocarsen has been studied as a single agent, as well as in combination with standard chemotherapeutics, in cancer patients in over 20 trials from phase I to phase III (reviewed in <xref rid="bib61 bib62" ref-type="bibr">[61,62]</xref>). The studies include individuals with non-small cell lung cancer <xref rid="bib63" ref-type="bibr">[63]</xref>, colon <xref rid="bib64" ref-type="bibr">[64]</xref>, ovarian <xref rid="bib65" ref-type="bibr">[65]</xref>, breast <xref rid="bib66" ref-type="bibr">[66]</xref> and prostate cancers <xref rid="bib67" ref-type="bibr">[67]</xref> and non-Hodgkin's lymphoma <xref rid="bib68" ref-type="bibr">[68]</xref>. Although encouraging results have been observed in phase II trials, disappointingly aprinocarsen has failed to meet efficacy endpoints in phase III trials when used in combination with conventional chemotherapy for late-stage lung cancer <xref rid="bib69 bib70" ref-type="bibr">[69,70]</xref>. Reasons for this lack of efficacy could be manifold, including lack of prior screening of patients for expression levels of PKCα, dose reduction due to toxicity during the trial and driving of cell proliferation by other related PKC isoforms <xref rid="bib69" ref-type="bibr">[69]</xref>.</p>
    </sec>
    <sec>
      <title>Conclusions</title>
      <p>PKCα plays important roles in several cellular processes and pathologies, involving cancer, cardiovascular disorders, atherogenesis and thrombosis. Its ubiquity and multiple roles, however, present a potential difficulty in its use as a drug target, although the mutual functional redundancy of various PKC isoforms might help to overcome possible unwanted effects of specific pharmacological intervention. It is clear, for instance, that thrombus formation is markedly diminished in the <italic>Prkca</italic><sup>−/−</sup> mouse, whereas haemostasis is normal <xref rid="bib4" ref-type="bibr">[4]</xref>. This functional redundancy with related PKC isoforms may also obscure other potential roles for PKCα, determined in particular from gene knockout strategies. There are clearly many strategies that can be adopted to target this kinase therapeutically (<xref rid="tb1" ref-type="boxed-text">Box 1</xref>), and in this regard a key advance will be the determination of the crystal structure of the catalytic domain of PKCα. It will be important to continue developing strategies for PKCα targeting in the future, because specific drug targeting could have great value in the treatment of multiple disease states.</p>
    </sec>
    <sec>
      <title>Conflict of interest declaration</title>
      <p>The authors have declared that no conflict of interest exists.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors thank Drs Matthew Jones and Matthew Harper for their advice and critical reading of the manuscript. Work in the authors’ laboratory is supported by grants from the British Heart Foundation (grant nos. RG/05/015 and PG/07/118/24152).</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parker</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Murray-Rust</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>PKC at a glance</article-title>
          <source>J. Cell Sci.</source>
          <year>2004</year>
          <volume>117</volume>
          <fpage>131</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">14676268</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oster</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Leitges</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase Cα but not PKCζ suppresses intestinal tumor formation in ApcMin/+ mice</article-title>
          <source>Cancer Res.</source>
          <year>2006</year>
          <volume>66</volume>
          <fpage>6955</fpage>
          <lpage>6963</lpage>
          <pub-id pub-id-type="pmid">16849539</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braz</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>PKCα regulates cardiac contractility and propensity toward heart failure</article-title>
          <source>Nat. Med.</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>248</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="pmid">14966518</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konopatskaya</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>PKCα regulates platelet granule secretion and thrombus formation in mice</article-title>
          <source>J. Clin. Invest.</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>399</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="pmid">19147982</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Churchill</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>PKC isozymes in chronic cardiac disease: possible therapeutic targets?</article-title>
          <source>Annu. Rev. Pharmacol. Toxicol.</source>
          <year>2008</year>
          <volume>48</volume>
          <fpage>569</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="pmid">17919087</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Palaniyandi</surname>
              <given-names>S.S.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C in heart failure: a therapeutic target?</article-title>
          <source>Cardiovasc. Res.</source>
          <year>2009</year>
          <volume>82</volume>
          <fpage>229</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">19168855</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mackay</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Twelves</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>Targeting the protein kinase C family: are we there yet?</article-title>
          <source>Nat. Rev. Cancer</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>554</fpage>
          <lpage>562</lpage>
          <pub-id pub-id-type="pmid">17585335</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dempsey</surname>
              <given-names>E.C.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C isozymes and the regulation of diverse cell responses</article-title>
          <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source>
          <year>2000</year>
          <volume>279</volume>
          <fpage>L429</fpage>
          <lpage>438</lpage>
          <pub-id pub-id-type="pmid">10956616</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gould</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Newton</surname>
              <given-names>A.C.</given-names>
            </name>
          </person-group>
          <article-title>The life and death of protein kinase C</article-title>
          <source>Curr. Drug Targets</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>614</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="pmid">18691009</pub-id>
        </citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakashima</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase Cα (PKCα): regulation and biological function</article-title>
          <source>J. Biochem.</source>
          <year>2002</year>
          <volume>132</volume>
          <fpage>669</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="pmid">12417014</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leitges</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Knockout of PKCα enhances insulin signaling through PI3K</article-title>
          <source>Mol. Endocrinol.</source>
          <year>2002</year>
          <volume>16</volume>
          <fpage>847</fpage>
          <lpage>858</lpage>
          <pub-id pub-id-type="pmid">11923480</pub-id>
        </citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pfeifhofer</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Defective IgG2a/2b class switching in PKCα-/- mice</article-title>
          <source>J. Immunol.</source>
          <year>2006</year>
          <volume>176</volume>
          <fpage>6004</fpage>
          <lpage>6011</lpage>
          <pub-id pub-id-type="pmid">16670309</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von Essen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C (PKC) α and PKCθ are the major PKC isotypes involved in TCR down-regulation</article-title>
          <source>J. Immunol.</source>
          <year>2006</year>
          <volume>176</volume>
          <fpage>7502</fpage>
          <lpage>7510</lpage>
          <pub-id pub-id-type="pmid">16751397</pub-id>
        </citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vijayan</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase Cα-induced hypertrophy of neonatal rat ventricular myocytes</article-title>
          <source>Am. J. Physiol. Heart Circ. Physiol.</source>
          <year>2004</year>
          <volume>287</volume>
          <fpage>H2777</fpage>
          <lpage>2789</lpage>
          <pub-id pub-id-type="pmid">15271671</pub-id>
        </citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerkela</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Identification of PKCα isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides</article-title>
          <source>Mol. Pharmacol.</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>1482</fpage>
          <lpage>1491</lpage>
          <pub-id pub-id-type="pmid">12435817</pub-id>
        </citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braz</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>PKCα regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2)</article-title>
          <source>J. Cell Biol.</source>
          <year>2002</year>
          <volume>156</volume>
          <fpage>905</fpage>
          <lpage>919</lpage>
          <pub-id pub-id-type="pmid">11864993</pub-id>
        </citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belin</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>Augmented protein kinase Cα-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure</article-title>
          <source>Circ. Res.</source>
          <year>2007</year>
          <volume>101</volume>
          <fpage>195</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">17556659</pub-id>
        </citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sumandea</surname>
              <given-names>M.P.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T</article-title>
          <source>J. Biol. Chem.</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>35135</fpage>
          <lpage>35144</lpage>
          <pub-id pub-id-type="pmid">12832403</pub-id>
        </citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holm</surname>
              <given-names>P.W.</given-names>
            </name>
          </person-group>
          <article-title>Atherosclerotic plaque development and instability: a dual role for VEGF</article-title>
          <source>Ann. Med.</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>257</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="pmid">19089693</pub-id>
        </citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rask-Madsen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>G.L.</given-names>
            </name>
          </person-group>
          <article-title>Differential regulation of VEGF signaling by PKCα and PKCɛ in endothelial cells</article-title>
          <source>Arterioscler Thromb. Vasc. Biol.</source>
          <year>2008</year>
          <volume>28</volume>
          <fpage>919</fpage>
          <lpage>924</lpage>
          <pub-id pub-id-type="pmid">18323518</pub-id>
        </citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth</article-title>
          <source>J. Clin. Invest.</source>
          <year>1996</year>
          <volume>98</volume>
          <fpage>2018</fpage>
          <lpage>2026</lpage>
          <pub-id pub-id-type="pmid">8903320</pub-id>
        </citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goekjian</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Jirousek</surname>
              <given-names>M.R.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C inhibitors as novel anticancer drugs</article-title>
          <source>Expert Opin. Investig. Drugs</source>
          <year>2001</year>
          <volume>10</volume>
          <fpage>2117</fpage>
          <lpage>2140</lpage>
        </citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of protein kinase Cα prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo</article-title>
          <source>Circ. Res.</source>
          <year>2002</year>
          <volume>90</volume>
          <fpage>609</fpage>
          <lpage>616</lpage>
          <pub-id pub-id-type="pmid">11909826</pub-id>
        </citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase Cα promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor</article-title>
          <source>Cardiovasc. Res.</source>
          <year>2008</year>
          <volume>78</volume>
          <fpage>349</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="pmid">18056764</pub-id>
        </citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrington</surname>
              <given-names>E.O.</given-names>
            </name>
          </person-group>
          <article-title>Endothelial proliferation, migration, and differentiation are blunted by conditionally expressed protein kinase C pseudosubstrate peptides</article-title>
          <source>Biochem. Biophys Res. Commun.</source>
          <year>2000</year>
          <volume>271</volume>
          <fpage>499</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="pmid">10799325</pub-id>
        </citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mountain</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs</article-title>
          <source>Am. J. Physiol. Cell Physiol.</source>
          <year>2007</year>
          <volume>292</volume>
          <fpage>C867</fpage>
          <lpage>875</lpage>
          <pub-id pub-id-type="pmid">16987994</pub-id>
        </citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aghajanian</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration</article-title>
          <source>J. Thromb. Haemost.</source>
          <year>2008</year>
          <volume>6</volume>
          <fpage>1453</fpage>
          <lpage>1460</lpage>
          <pub-id pub-id-type="pmid">18647230</pub-id>
        </citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lum</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Malik</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of vascular endothelial barrier function</article-title>
          <source>Am. J. Physiol.</source>
          <year>1994</year>
          <volume>267</volume>
          <fpage>L223</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="pmid">7943249</pub-id>
        </citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandoval</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Ca(2+) signalling and PKCα activate increased endothelial permeability by disassembly of VE-cadherin junctions</article-title>
          <source>J. Physiol.</source>
          <year>2001</year>
          <volume>533</volume>
          <fpage>433</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="pmid">11389203</pub-id>
        </citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tiruppathi</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Role of Ca2+ signaling in the regulation of endothelial permeability</article-title>
          <source>Vascul. Pharmacol.</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>173</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">12747958</pub-id>
        </citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmmed</surname>
              <given-names>G.U.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase Cα phosphorylates the TRPC1 channel and regulates store-operated Ca2+ entry in endothelial cells</article-title>
          <source>J. Biol. Chem.</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>20941</fpage>
          <lpage>20949</lpage>
          <pub-id pub-id-type="pmid">15016832</pub-id>
        </citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function</article-title>
          <source>J. Biol. Chem.</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>22614</fpage>
          <lpage>22620</lpage>
          <pub-id pub-id-type="pmid">11309397</pub-id>
        </citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stamatovic</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability</article-title>
          <source>J. Biol. Chem.</source>
          <year>2006</year>
          <volume>281</volume>
          <fpage>8379</fpage>
          <lpage>8388</lpage>
          <pub-id pub-id-type="pmid">16439355</pub-id>
        </citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferro</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha</article-title>
          <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source>
          <year>2000</year>
          <volume>278</volume>
          <fpage>L1107</fpage>
          <lpage>1117</lpage>
          <pub-id pub-id-type="pmid">10835315</pub-id>
        </citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lum</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction</article-title>
          <source>Am. J. Physiol. Lung Cell Mol. Physiol.</source>
          <year>2001</year>
          <volume>281</volume>
          <fpage>L546</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">11504680</pub-id>
        </citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hempel</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha</article-title>
          <source>Circ. Res.</source>
          <year>1997</year>
          <volume>81</volume>
          <fpage>363</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">9285638</pub-id>
        </citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Witztum</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Steinberg</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Role of oxidized low density lipoprotein in atherogenesis</article-title>
          <source>J. Clin. Invest.</source>
          <year>1991</year>
          <volume>88</volume>
          <fpage>1785</fpage>
          <lpage>1792</lpage>
          <pub-id pub-id-type="pmid">1752940</pub-id>
        </citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleming</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha</article-title>
          <source>Cardiovasc. Res.</source>
          <year>2005</year>
          <volume>65</volume>
          <fpage>897</fpage>
          <lpage>906</lpage>
          <pub-id pub-id-type="pmid">15721870</pub-id>
        </citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition</article-title>
          <source>Eur. J. Pharmacol.</source>
          <year>2006</year>
          <volume>552</volume>
          <fpage>162</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="pmid">17067573</pub-id>
        </citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawakami</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation</article-title>
          <source>Arterioscler Thromb. Vasc. Biol.</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>219</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="pmid">17038637</pub-id>
        </citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gong</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Lactosylceramide recruits PKCalpha/epsilon and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells</article-title>
          <source>Proc. Natl. Acad. Sci. U. S. A.</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>6490</fpage>
          <lpage>6495</lpage>
          <pub-id pub-id-type="pmid">15084746</pub-id>
        </citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fu</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Protease-activated receptor-1 activation of endothelial cells induces protein kinase Calpha-dependent phosphorylation of syntaxin 4 and Munc18c: role in signaling p-selectin expression</article-title>
          <source>J. Biol. Chem.</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>3178</fpage>
          <lpage>3184</lpage>
          <pub-id pub-id-type="pmid">15576373</pub-id>
        </citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meadows</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Clinical aspects of platelet inhibitors and thrombus formation</article-title>
          <source>Circ. Res.</source>
          <year>2007</year>
          <volume>100</volume>
          <fpage>1261</fpage>
          <lpage>1275</lpage>
          <pub-id pub-id-type="pmid">17495233</pub-id>
        </citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harper</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Poole</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>Isoform-specific functions of protein kinase C: the platelet paradigm</article-title>
          <source>Biochem. Soc. Trans.</source>
          <year>2007</year>
          <volume>35</volume>
          <fpage>1005</fpage>
          <lpage>1008</lpage>
          <pub-id pub-id-type="pmid">17956264</pub-id>
        </citation>
      </ref>
      <ref id="bib45">
        <label>45</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshioka</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Identification of protein kinase Calpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alpha- and dense-core granule secretion in platelets</article-title>
          <source>J. Biol. Chem.</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>39379</fpage>
          <lpage>39385</lpage>
          <pub-id pub-id-type="pmid">11495897</pub-id>
        </citation>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabuchi</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Direct demonstration of involvement of protein kinase Calpha in the Ca2+-induced platelet aggregation</article-title>
          <source>J. Biol. Chem.</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>26374</fpage>
          <lpage>26379</lpage>
          <pub-id pub-id-type="pmid">12724315</pub-id>
        </citation>
      </ref>
      <ref id="bib47">
        <label>47</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pula</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Functional interaction of protein kinase Calpha with the tyrosine kinases Syk and Src in human platelets</article-title>
          <source>J. Biol. Chem.</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>7194</fpage>
          <lpage>7205</lpage>
          <pub-id pub-id-type="pmid">15583006</pub-id>
        </citation>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3</article-title>
          <source>Curr. Biol.</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>1796</fpage>
          <lpage>1806</lpage>
          <pub-id pub-id-type="pmid">16979556</pub-id>
        </citation>
      </ref>
      <ref id="bib49">
        <label>49</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fields</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>N.R.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C isozymes as therapeutic targets for treatment of human cancers</article-title>
          <source>Adv. Enzyme Regul.</source>
          <year>2008</year>
          <volume>48</volume>
          <fpage>166</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="pmid">18167314</pub-id>
        </citation>
      </ref>
      <ref id="bib50">
        <label>50</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koivunen</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells</article-title>
          <source>Cancer Res.</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>5693</fpage>
          <lpage>5701</lpage>
          <pub-id pub-id-type="pmid">15313909</pub-id>
        </citation>
      </ref>
      <ref id="bib51">
        <label>51</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masur</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells</article-title>
          <source>Mol. Biol. Cell</source>
          <year>2001</year>
          <volume>12</volume>
          <fpage>1973</fpage>
          <lpage>1982</lpage>
          <pub-id pub-id-type="pmid">11451996</pub-id>
        </citation>
      </ref>
      <ref id="bib52">
        <label>52</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fournier</surname>
              <given-names>D.B.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer</article-title>
          <source>Gynecol. Oncol.</source>
          <year>2001</year>
          <volume>81</volume>
          <fpage>366</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="pmid">11371124</pub-id>
        </citation>
      </ref>
      <ref id="bib53">
        <label>53</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koren</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate</article-title>
          <source>Oncol. Rep.</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>321</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="pmid">14719062</pub-id>
        </citation>
      </ref>
      <ref id="bib54">
        <label>54</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langzam</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy</article-title>
          <source>Am. J. Clin. Pathol.</source>
          <year>2001</year>
          <volume>116</volume>
          <fpage>377</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="pmid">11554166</pub-id>
        </citation>
      </ref>
      <ref id="bib55">
        <label>55</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Varga</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas</article-title>
          <source>Eur. Urol.</source>
          <year>2004</year>
          <volume>46</volume>
          <fpage>462</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="pmid">15363561</pub-id>
        </citation>
      </ref>
      <ref id="bib56">
        <label>56</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lahn</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The role of protein kinase C-alpha in hematologic malignancies</article-title>
          <source>Acta Haematol.</source>
          <year>2006</year>
          <volume>115</volume>
          <fpage>1</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">16424642</pub-id>
        </citation>
      </ref>
      <ref id="bib57">
        <label>57</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neill</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Loss of protein kinase Calpha expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma</article-title>
          <source>Cancer Res.</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>4692</fpage>
          <lpage>4697</lpage>
          <pub-id pub-id-type="pmid">12907651</pub-id>
        </citation>
      </ref>
      <ref id="bib58">
        <label>58</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lahn</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C alpha expression in breast and ovarian cancer</article-title>
          <source>Oncology</source>
          <year>2004</year>
          <volume>67</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">15459489</pub-id>
        </citation>
      </ref>
      <ref id="bib59">
        <label>59</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors</article-title>
          <source>Oncogene</source>
          <year>2006</year>
          <volume>25</volume>
          <fpage>3286</fpage>
          <lpage>3295</lpage>
          <pub-id pub-id-type="pmid">16407820</pub-id>
        </citation>
      </ref>
      <ref id="bib60">
        <label>60</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerfoot</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha</article-title>
          <source>J. Histochem. Cytochem.</source>
          <year>2004</year>
          <volume>52</volume>
          <fpage>419</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="pmid">14966210</pub-id>
        </citation>
      </ref>
      <ref id="bib61">
        <label>61</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanauske</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen</article-title>
          <source>Curr. Pharm. Des.</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>1923</fpage>
          <lpage>1936</lpage>
          <pub-id pub-id-type="pmid">15180529</pub-id>
        </citation>
      </ref>
      <ref id="bib62">
        <label>62</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>ISIS-3521. Isis Pharmaceuticals</article-title>
          <source>Curr. Opin. Investig. Drugs</source>
          <year>2001</year>
          <volume>2</volume>
          <fpage>1454</fpage>
          <lpage>1461</lpage>
        </citation>
      </ref>
      <ref id="bib63">
        <label>63</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villalona-Calero</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer</article-title>
          <source>Clin. Cancer Res.</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>6086</fpage>
          <lpage>6093</lpage>
          <pub-id pub-id-type="pmid">15447994</pub-id>
        </citation>
      </ref>
      <ref id="bib64">
        <label>64</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marshall</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer</article-title>
          <source>Clin. Colorectal. Cancer</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>268</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="pmid">15555210</pub-id>
        </citation>
      </ref>
      <ref id="bib65">
        <label>65</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Advani</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma</article-title>
          <source>Cancer</source>
          <year>2004</year>
          <volume>100</volume>
          <fpage>321</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="pmid">14716767</pub-id>
        </citation>
      </ref>
      <ref id="bib66">
        <label>66</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roychowdhury</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lahn</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer</article-title>
          <source>Semin Oncol.</source>
          <year>2003</year>
          <volume>30</volume>
          <fpage>30</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">12722024</pub-id>
        </citation>
      </ref>
      <ref id="bib67">
        <label>67</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tolcher</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer</article-title>
          <source>Clin. Cancer Res.</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>2530</fpage>
          <lpage>2535</lpage>
          <pub-id pub-id-type="pmid">12171880</pub-id>
        </citation>
      </ref>
      <ref id="bib68">
        <label>68</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rao</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma</article-title>
          <source>Ann. Oncol.</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>1413</fpage>
          <lpage>1418</lpage>
          <pub-id pub-id-type="pmid">15319248</pub-id>
        </citation>
      </ref>
      <ref id="bib69">
        <label>69</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paz-Ares</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer</article-title>
          <source>J. Clin. Oncol.</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>1428</fpage>
          <lpage>1434</lpage>
          <pub-id pub-id-type="pmid">16549837</pub-id>
        </citation>
      </ref>
      <ref id="bib70">
        <label>70</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roffey</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C intervention: the state of play</article-title>
          <source>Curr. Opin. Cell Biol.</source>
          <year>2009</year>
          <volume>21</volume>
          <fpage>268</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="pmid">19233632</pub-id>
        </citation>
      </ref>
      <ref id="bib71">
        <label>71</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cole</surname>
              <given-names>D.C.</given-names>
            </name>
          </person-group>
          <article-title>Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors</article-title>
          <source>J. Med. Chem.</source>
          <year>2008</year>
          <volume>51</volume>
          <fpage>5958</fpage>
          <lpage>5963</lpage>
          <pub-id pub-id-type="pmid">18783200</pub-id>
        </citation>
      </ref>
      <ref id="bib72">
        <label>72</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <article-title>Protein Kinase C{alpha}, but Not PKC{beta} or PKC{gamma}, Regulates Contractility and Heart Failure Susceptibility. Implications for Ruboxistaurin As a Novel Therapeutic Approach</article-title>
          <source>Circ. Res.</source>
          <year>2009</year>
          <volume>105</volume>
          <fpage>194</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">19556521</pub-id>
        </citation>
      </ref>
      <ref id="bib73">
        <label>73</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y.B.</given-names>
            </name>
            <name>
              <surname>LaCasce</surname>
              <given-names>A.S.</given-names>
            </name>
          </person-group>
          <article-title>Enzastaurin</article-title>
          <source>Expert Opin. Investig. Drugs</source>
          <year>2008</year>
          <volume>17</volume>
          <fpage>939</fpage>
          <lpage>944</lpage>
        </citation>
      </ref>
      <ref id="bib74">
        <label>74</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Das Evcimen</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>G.L.</given-names>
            </name>
          </person-group>
          <article-title>The role of protein kinase C activation and the vascular complications of diabetes</article-title>
          <source>Pharmacol. Res.</source>
          <year>2007</year>
          <volume>55</volume>
          <fpage>498</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">17574431</pub-id>
        </citation>
      </ref>
      <ref id="bib75">
        <label>75</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rademaker-Lakhai</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer</article-title>
          <source>Clin. Cancer Res.</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>4474</fpage>
          <lpage>4481</lpage>
          <pub-id pub-id-type="pmid">17671132</pub-id>
        </citation>
      </ref>
      <ref id="bib76">
        <label>76</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herbert</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Chelerythrine is a potent and specific inhibitor of protein kinase C</article-title>
          <source>Biochem. Biophys Res. Commun.</source>
          <year>1990</year>
          <volume>172</volume>
          <fpage>993</fpage>
          <lpage>999</lpage>
          <pub-id pub-id-type="pmid">2244923</pub-id>
        </citation>
      </ref>
      <ref id="bib77">
        <label>77</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szallasi</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts</article-title>
          <source>J. Biol. Chem.</source>
          <year>1994</year>
          <volume>269</volume>
          <fpage>2118</fpage>
          <lpage>2124</lpage>
          <pub-id pub-id-type="pmid">8294465</pub-id>
        </citation>
      </ref>
      <ref id="bib78">
        <label>78</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wender</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Function-oriented synthesis, step economy, and drug design</article-title>
          <source>Acc. Chem. Res.</source>
          <year>2008</year>
          <volume>41</volume>
          <fpage>40</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">18159936</pub-id>
        </citation>
      </ref>
      <ref id="bib79">
        <label>79</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruns</surname>
              <given-names>R.F.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of protein kinase C by calphostin C is light-dependent</article-title>
          <source>Biochem. Biophys Res. Commun.</source>
          <year>1991</year>
          <volume>176</volume>
          <fpage>288</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="pmid">1708246</pub-id>
        </citation>
      </ref>
      <ref id="bib80">
        <label>80</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poole</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>PKC-interacting proteins: from function to pharmacology</article-title>
          <source>Trends Pharmacol. Sci.</source>
          <year>2004</year>
          <volume>25</volume>
          <fpage>528</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="pmid">15380937</pub-id>
        </citation>
      </ref>
      <ref id="bib81">
        <label>81</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Churchill</surname>
              <given-names>E.N.</given-names>
            </name>
          </person-group>
          <article-title>Rationally designed peptide regulators of protein kinase C</article-title>
          <source>Trends Endocrinol. Metab.</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>25</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">19056296</pub-id>
        </citation>
      </ref>
      <ref id="bib82">
        <label>82</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bates</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction</article-title>
          <source>Circulation</source>
          <year>2008</year>
          <volume>117</volume>
          <fpage>886</fpage>
          <lpage>896</lpage>
          <pub-id pub-id-type="pmid">18250271</pub-id>
        </citation>
      </ref>
      <ref id="bib83">
        <label>83</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martelli</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Molecular characterization of protein kinase C-alpha binding to lamin A</article-title>
          <source>J. Cell Biochem.</source>
          <year>2002</year>
          <volume>86</volume>
          <fpage>320</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">12112001</pub-id>
        </citation>
      </ref>
      <ref id="bib84">
        <label>84</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabellini</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Binding of elements of protein kinase C-alpha regulatory domain to lamin B1</article-title>
          <source>Cell Signal.</source>
          <year>2002</year>
          <volume>14</volume>
          <fpage>819</fpage>
          <lpage>827</lpage>
          <pub-id pub-id-type="pmid">12135703</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p><bold>PKCα plays key physiological and pathological roles.</bold> The ubiquitously expressed protein kinase PKCα plays roles in multiple cellular processes, including many not detailed in the Figure. Depicted are the three areas discussed principally in the text where PKCα has been shown to play a role in regulating cardiac and vascular function, platelet function and thrombosis, and cellular proliferation and migration in cancers. In brief, PKCα negatively regulates myocardial contractility, positively regulates angiogenesis and monocyte adhesion to endothelial cells in atherosclerosis development, positively regulates platelet aggregation and thrombus formation in arteries and variously regulates tumor progression, depending upon cell type and nature of the cancer.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p><bold>PKCα plays a critical role regulating platelet function and thrombosis in arteries.</bold> Platelets are the smallest cellular component of the blood, and flow close to the endothelial lining of arteries continually surveying the vessel for breaches in endothelial integrity. In the main panel platelets are depicted encountering such a breach, exposing subendothelial collagen to which platelets adhere and activate. Critical for the rapid build up of a platelet aggregate, or thrombus, is the release of positive feedback mediators, many of which, including ADP which acts on its receptors P2Y<sub>1</sub> and P2Y<sub>12</sub>, are contained in secretory granules in platelets. The expanded inset figure illustrates that PKCα plays a crucial role mediating signals from the platelet collagen receptor, GPVI, to release of granule contents, including ADP, and also to activation of the major adhesion molecule, integrin α<sub>IIb</sub>β<sub>3</sub>. This integrin bridges platelets through binding the plasma protein fibrinogen. Platelet–platelet interaction and subsequent build up of a thrombus in arteries is therefore dependent upon platelet PKCα. Arterial thrombus formation is the major occlusive event underlying vessel blockage in heart disease and thrombotic stroke, and therefore platelet PKCα may represent a novel target for therapeutic intervention.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Figure I</label>
      <caption>
        <p>PKCα domain structure mapped against pharmacological inhibitors. The structure comprises an N-terminal regulatory domain, consisting of the diacylglycerol (DAG)-binding C1 domain and the Ca<sup>2+</sup>-binding C2 domain, and a C-terminal catalytic domain, consisting of an ATP-binding pocket followed by the substrate-binding domain. Each component of the molecule is a potential target for pharmacological intervention, as indicated by the drugs listed below the domains. Thus, bryostatin and calphostin C target the C1 domain, RACK peptides mimic the C2 domain region of protein-protein interaction, staurosporine and its derivatives target the ATP binding pocket, whilst peptides that mimic the pseudosubstrate domain, and chelerythrine, bind to the substrate-binding domain. Not illustrated here is the use of genetic tools, such as antisense drugs (e.g. aprinocarsen), that can alter the expression of the protein in cells and tissues.</p>
      </caption>
      <graphic xlink:href="gr1b1"/>
    </fig>
    <boxed-text id="tb1">
      <label>Box 1</label>
      <title>Approaches to targeting PKCα</title>
      <p>Several approaches are used to target PKCα therapeutically, as summarized in <xref rid="fig3" ref-type="fig">Figure I</xref>.<list list-type="simple"><list-item><label><bold>1.</bold></label><p><bold>ATP (adenosine triphosphate) binding site</bold></p></list-item></list></p>
      <p>The ATP binding site is attractive for drug targeting, although selectivity may be difficult to achieve due to conservation of sequence and structure for this domain within the PKC family. The high concentration of ATP competes also with inhibitors at this site, decreasing their apparent activity. However, this site is still highly attractive for drug development, particularly by structure-based approaches, which are proving useful for PKCθ inhibitors <xref rid="bib71" ref-type="bibr">[71]</xref>. A publicly available crystal structure for PKCα is still absent, and is clearly a requirement for future development.</p>
      <p>Some bisinolylmaleimides, derivatives of staurosporine, show good selectivity within the PKC family. Ruboxistaurin (LY333531) and enzostaurin (LY317615) are designed to selectively target PKCβ, although a recent report suggests that ruboxistaurin may inhibit PKCα equipotently <xref rid="bib72" ref-type="bibr">[72]</xref>. Both enzastaurin and ruboxistaurin are well tolerated <xref rid="bib73 bib74" ref-type="bibr">[73,74]</xref>. Enzastaurin shows promise in phase I trials for the treatment of advanced cancer <xref rid="bib75" ref-type="bibr">[75]</xref>. Ruboxistaurin has completed phase III trials for the management of diabetic retinopathy <xref rid="bib70 bib74" ref-type="bibr">[70,74]</xref>, principally through targeting PKCβ.<list list-type="simple"><list-item><label><bold>2.</bold></label><p><bold>Peptide substrate mimetics</bold></p></list-item></list></p>
      <p>Peptide substrate mimetics are short peptides that resemble the preferred substrate sequence for PKCα, often mimicking the pseudosubstrate domain, and compete for substrate binding. In addition, a small-molecule inhibitor, chelerythrine, competitively binds to the substrate-binding pocket, although its specificity for PKCα is poor <xref rid="bib76" ref-type="bibr">[76]</xref>.<list list-type="simple"><list-item><label><bold>3.</bold></label><p><bold>C1 domain</bold></p></list-item></list></p>
      <p>The C1 domain binds diacylglycerol (DAG) and phorbol esters. Bryostatin is a macrocyclic lactone that competes with DAG for binding <xref rid="bib77" ref-type="bibr">[77]</xref>, and simplified analogues have been designed with improved activity <xref rid="bib78" ref-type="bibr">[78]</xref>. Calphostin C also binds PKCα, and other PKC isoforms, at the C1 domain. The inhibition is irreversible, and requires prior light activation of the molecule <xref rid="bib79" ref-type="bibr">[79]</xref>.<list list-type="simple"><list-item><label><bold>4.</bold></label><p><bold>C2 domain</bold></p></list-item></list></p>
      <p>The C2 domain binds Ca<sup>2+</sup> and mediates interaction with proteins <xref rid="bib80" ref-type="bibr">[80]</xref>, in particular Receptors-for-Activated-C-Kinase (RACKs) <xref rid="bib81" ref-type="bibr">[81]</xref>. RACK peptides therefore disrupt the localization of PKCs to their substrates, thereby effectively inhibiting their activity. This inhibition has been shown most extensively for PKCδ, where KAI-9803 is undergoing clinical trial for cardiac ST segment elevation of cardiogram in patients with myocardial infarction <xref rid="bib82" ref-type="bibr">[82]</xref>. PKCα interacts with fascin and lamin A, and inhibition of these interactions might disrupt cytoskeleton- and nucleus-dependent signalling <xref rid="bib83 bib84" ref-type="bibr">[83,84]</xref>.<list list-type="simple"><list-item><label><bold>5.</bold></label><p><bold>Gene therapy</bold></p></list-item></list></p>
      <p>Although not shown in <xref rid="fig3" ref-type="fig">Figure I</xref>, an antisense drug, aprinocarsen (ISIS 3521, LY900003), has been used to reduce expression of PKCα. This drug has undergone phase III clinical trials for the treatment of various human tumors <xref rid="bib61" ref-type="bibr">[61]</xref> but has not progressed through to the clinic, due to non-achievement of efficacy endpoints and associated toxicity.</p>
    </boxed-text>
  </floats-wrap>
</article>